120 related articles for article (PubMed ID: 11431583)
21. TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Behçet's disease.
Akman A; Sallakci N; Coskun M; Bacanli A; Yavuzer U; Alpsoy E; Yegin O
Br J Dermatol; 2006 Aug; 155(2):350-6. PubMed ID: 16882174
[TBL] [Abstract][Full Text] [Related]
22. Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial.
Davatchi F; Sadeghi Abdollahi B; Tehrani Banihashemi A; Shahram F; Nadji A; Shams H; Chams-Davatchi C
Mod Rheumatol; 2009; 19(5):542-9. PubMed ID: 19597921
[TBL] [Abstract][Full Text] [Related]
23. Serum leptin levels in patients with ocular and nonocular Behçet's disease.
Yalçindağ FN; Kisa U; Batioğlu F; Yalçindağ A; Ozdemir O; Cağlayan O
Mediators Inflamm; 2007; 2007():31986. PubMed ID: 17641728
[TBL] [Abstract][Full Text] [Related]
24. Serum levels of GRO-α are elevated in association with disease activity in patients with Behçet's disease.
Kato Y; Yamamoto T
Int J Dermatol; 2012 Mar; 51(3):286-9. PubMed ID: 22348563
[TBL] [Abstract][Full Text] [Related]
25. Comparison of serum nitric oxide, malondialdehyde levels, and antioxidant enzyme activities in Behçet's disease with and without ocular disease.
Aydin E; Sögüt S; Ozyurt H; Ozugurlu F; Akyol O
Ophthalmic Res; 2004; 36(3):177-82. PubMed ID: 15103210
[TBL] [Abstract][Full Text] [Related]
26. The Effect of Colchicine on Mean Platelet Volume in Behcet's Disease.
Ataş H; Cemil BC; Canpolat F; Gönül M
Ann Clin Lab Sci; 2015; 45(5):545-9. PubMed ID: 26586706
[TBL] [Abstract][Full Text] [Related]
27. Lipoprotein (a) and nitrites in Behcet's disease: relationship with disease activity and vascular complications.
Esmat S; El Sherif H; Anwar S; Fahmy I; Elmenyawi M; Shaker O
Eur J Dermatol; 2006; 16(1):67-71. PubMed ID: 16436346
[TBL] [Abstract][Full Text] [Related]
28. Serum mannose-binding lectin levels are decreased in behcet's disease and associated with disease severity.
Inanc N; Mumcu G; Birtas E; Elbir Y; Yavuz S; Ergun T; Fresko I; Direskeneli H
J Rheumatol; 2005 Feb; 32(2):287-91. PubMed ID: 15693089
[TBL] [Abstract][Full Text] [Related]
29. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
Donmez A; Aksu K; Celik HA; Keser G; Cagirgan S; Omay SB; Inal V; Aydin HH; Tombuloglu M; Doganavsargil E
Thromb Res; 2005; 115(4):287-92. PubMed ID: 15668188
[TBL] [Abstract][Full Text] [Related]
30. Significance of serum interleukin-8 levels in patients with Behcet's disease: high levels may indicate vascular involvement.
Durmazlar SP; Ulkar GB; Eskioglu F; Tatlican S; Mert A; Akgul A
Int J Dermatol; 2009 Mar; 48(3):259-64. PubMed ID: 19261013
[TBL] [Abstract][Full Text] [Related]
31. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis.
Ahn JK; Seo JM; Yu J; Oh FS; Chung H; Yu HG
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2458-64. PubMed ID: 15980236
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor levels of oral and genital ulcers and skin pathergy test in patients with Behçet's disease.
Alpsoy E; Elpek GO; Yilmaz F; Ciftcioglu MA; Akman A; Uzun S; Karakuzu A
Dermatology; 2005; 210(1):31-5. PubMed ID: 15604542
[TBL] [Abstract][Full Text] [Related]
33. Plasma homocysteine level and uveitis in Behçet's disease.
Okka M; Oztürk M; Kockar MC; Bavbek N; Rasier Y; Gunduz K
Isr Med Assoc J; 2002 Nov; 4(11 Suppl):931-4. PubMed ID: 12455183
[TBL] [Abstract][Full Text] [Related]
34. Circulating prolactin levels and Behcet's disease: A meta-analysis.
Song GG; Lee YH
Cell Mol Biol (Noisy-le-grand); 2018 Jan; 64(1):14-18. PubMed ID: 29412808
[TBL] [Abstract][Full Text] [Related]
35. Oxidative stress in patients with Behcet's disease: I correlation with severity and clinical parameters.
Najim RA; Sharquie KE; Abu-Raghif AR
J Dermatol; 2007 May; 34(5):308-14. PubMed ID: 17408439
[TBL] [Abstract][Full Text] [Related]
36. Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity.
Lee YJ; Kang SW; Song JK; Park JJ; Bae YD; Lee EY; Lee EB; Song YW
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S41-5. PubMed ID: 17949550
[TBL] [Abstract][Full Text] [Related]
37. Behçet's disease in an HIV-1-infected patient treated with highly active antiretroviral therapy.
Gómez-Puerta JA; Espinosa G; Miró JM; Sued O; Llibre JM; Cervera R; Font J
Isr Med Assoc J; 2006 Jul; 8(7):513-4. PubMed ID: 16889175
[No Abstract] [Full Text] [Related]
38. Epidemiologic and clinical aspects of Behçet's disease in a defined area of Northwestern Spain, 1988-1997.
González-Gay MA; García-Porrúa C; Brañas F; López-Lázaro L; Olivieri I
J Rheumatol; 2000 Mar; 27(3):703-7. PubMed ID: 10743812
[TBL] [Abstract][Full Text] [Related]
39. Serum endocan levels as a marker of disease activity in patients with Behçet disease.
Balta I; Balta S; Koryurek OM; Demirkol S; Mikhailidis DP; Celik T; Cakar M; Kucuk U; Eksioglu M; Kurt YG
J Am Acad Dermatol; 2014 Feb; 70(2):291-6. PubMed ID: 24176522
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of Angiopoietin-1 in Behcet's disease patients with vascular involvement.
Bassyouni IH; Sharaf M; Wali IE; Mansour HM
Heart Vessels; 2016 Jun; 31(6):918-24. PubMed ID: 25964071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
